Key result
Osfit stent achieves 100% successful implantation in coronary ostial lesions without protrusion or missing the ostium.
Why the study?
Stent implantation for coronary ostial lesions is challenging, prompting evaluation of the feasibility, safety, and immediate procedural results of the novel Osfit™ sirolimus drug-eluting stent delivery system.
Does the Osfit sirolimus-eluting stent system improve procedural accuracy and safety in patients undergoing percutaneous coronary intervention for coronary ostial lesions?
Observational (n=49)
No
Does the Osfit sirolimus-eluting stent system improve procedural accuracy and safety in patients undergoing percutaneous coronary intervention for coronary ostial lesions?
The novel Osfit stent delivery system, utilizing a proximal balloon stopper, demonstrated high procedural success and safety for treating coronary ostial lesions without geographic miss.
Supports feasibility of Osfit stent for ostial lesions; hypothesis-generating and should not change practice without randomized trials.
BACKGROUND AND OBJECTIVES: Stent implantation for coronary ostial lesions is challenging. This study evaluated the feasibility, safety, and immediate procedural results of the Osfit™, innovatively designed sirolimus drug-eluting stent delivery system for the treatment of coronary ostial lesions. METHODS: The Osfit™ has a 5 mm long extended balloon proximal to the stent (bare balloon without mounted stent). When inflated at 1.5 atm, only bare balloon inflated and acts like a stopper. We evaluated the technical feasibility in 49 patients with a coronary ostial lesion (defined as stenosis within 3 mm from the origin of the vessel) who had received the Osfit™. Intravascular ultrasound (IVUS) analysis was done in 11 patients who consented to IVUS examination, and the depth from the proximal edge of the stent to the ostial plane (DSO) was measured. RESULTS: In all 49 lesions, stents were successfully implanted in one single angiographic view without obvious stent protrusion or definite angiographic missing of the ostium. The proportions of aorto-ostial, and bifurcation lesions were 28.6% and 71.4%, respectively. The DSO was 0.2±0.69 mm, and the proximal stent edges were located within 1 mm of the ostial edge in all patients. No adverse events like death, myocardial infarction, target lesion revascularization, target vessel revascularization or stent thrombosis were reported during the in-hospital period or within 30 days. CONCLUSIONS: The implantation of the Osfit™ for coronary ostial lesions appears to be an accurate and safe procedure that may reduce multiple angiographic projections and advanced skills.
No takes yet. Share an insight, caveat, or question.
Seo et al. (2025) conducted an observational in Coronary ostial lesions (n=49). Osfit stent was evaluated on Successful stent implantation in a single angiographic view without obvious protrusion or missing the ostium.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: